Previous 10 | Next 10 |
BAUDETTE, Minn. , Jan. 9, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up to $25M in contingent profit share p...
BAUDETTE, Minn. , Dec. 18, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Bretylium Tosylate Injection USP, 50 mg/mL. Bretylium Tosylate is a class III antiarrhythmic medication approved for the treatment of ventricular fibri...
BAUDETTE, Minn. , Nov. 26, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston , Massachusetts. Arthur Przybyl, President and CEO, Robert Schrepfer , Senior Vice President Business...
ANI Pharmaceuticals (NASDAQ: ANIP ): Q3 Non-GAAP EPS of $1.23 misses by $0.20 ; GAAP EPS of $0.32 misses by $0.32 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BAUDETTE, Minn. , Nov. 6, 2019 /PRNewswire/ -- For the third quarter 2019: Net revenues of $51.3 million , an increase of 1% versus prior year GAAP net income of $3.9 million and diluted GAAP earnings per share of $0.32 Adjusted non-GAAP EBITDA of $19.8 milli...
BAUDETTE, Minn. , Oct. 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that its partner Pharmaceutics International Inc. (Pii) has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml)...
BAUDETTE, Minn. , Oct. 30, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2019 financial results on Wednesday, November 6, 2019 , before the opening of the U.S. financial markets. The...
BAUDETTE, Minn. , Oct. 29, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an experienced specialty pharmaceutical and contract development & manufacturing organization (CDMO), today announced the launch of its new CDMO brand, ANI Global Source. This ...
BAUDETTE, Minn. , Oct. 3, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the receipt of clinical data on Cortrophin® Gel (80 units/mL) from a study that evaluated the blood-level cortisol response in a 20-person healthy volunteer popul...
BAUDETTE, Minn. , Oct. 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg (the generic equivalent of Aggrenox®). This launch represents ANI's fifth generic product...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....